Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient mice

22 Dec 2009

Abstract excerpt

The threat of smallpox as a bioweapon and the emerging threat of human monkeypox, among other poxviral diseases, highlight the need for effective poxvirus countermeasures. ST-246, which targets the F13L protein in vaccinia virus and its homologs in other orthopoxvirus species, provides full protection from lethal poxviral disease in numerous animal models and seems to be safe in humans. All previous evaluations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Bacillus and Francisella bacterial research
Share to Herpesvirus Infections and Treatments
Share to Poxvirus research and outbreaks

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 20080762
DOI: 10.1073/pnas.0912134107

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient micePMID 20080762Read ↗

BoHV-4-Based Vector Single Heterologous Antigen Delivery Protects STAT1(-/-) Mice from Monkeypoxvirus Lethal ChallengeSemantic proximity Read ↗

Poxvirus Driven Human Diseases and Emerging TherapeuticsSemantic proximity Read ↗

Immune Response to Poxvirus Infections in Various AnimalsSemantic proximity Read ↗

The Global Health Threat of Monkeypox Virus: Understanding Its Biology, Transmission, and Potential Therapeutic InterventionsSemantic proximity Read ↗

Preventing the Next Pandemic: Is Live Vaccine Efficacious against Monkeypox, or Is There a Need for Killed Virus and mRNA Vaccines?Semantic proximity Read ↗

Non-replicating vaccinia virus NTV as an effective next-generation smallpox and monkeypox vaccine: evidence from mouse and rhesus monkey modelsSemantic proximity Read ↗

Strong and early monkeypox virus-specific immunity associated with mild disease after intradermal clade-IIb-infection in CAST/EiJ-miceSemantic proximity Read ↗

Oral Administration of the carboxylic acid ester prodrug NHC SN_9 protects mice from lethal Orthopoxvirus challenge: Implications for the Treatment of MonkeypoxSemantic proximity Read ↗

Recombinant chimeric Horsepox Virus (TNX-801) is attenuated relative to Vaccinia Virus Strains in Human Primary Cell Lines and in Immunocompromised MiceSemantic proximity Read ↗

In-silico formulation of a next-generation polyvalent vaccine against multiple strains of monkeypox virus and other related poxvirusesSemantic proximity Read ↗

JYNNEOS VS. ACAM2000: A CRITICAL REVIEW OF THE SAFETY, EFFICACY AND REAL-WORLD EFFECTIVENESS OF MONKEYPOX VACCINESSemantic proximity Read ↗

Genes that control vaccinia virus immunogenicitySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.